

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85183 A2

(51) International Patent Classification⁷: **A61K 35/00**

(21) International Application Number: PCT/NL01/00348

(22) International Filing Date: 8 May 2001 (08.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/566,385 8 May 2000 (08.05.2000) US

(71) Applicant (for all designated States except US): N.V. NUTRICIA [NL/NL]; P.O. Box 1, NL-2700 MA Zoetermeer (NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VERDEGEM, Peter, Julien, Edward [NL/NL]; Zwanenveld 2413, NL-6538 PA Nijmegen (NL).

(74) Agent: JORRITSMA, Ruurd; Nederlandsch Octroibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION FOR THE PREVENTION AND TREATMENT OF OCULAR DISORDERS

(57) Abstract: The present invention relates to a preparation for the prevention and/or treatment of ocular disorders which comprises: a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood flow. Component a can be *Chrysanthemum morifolium*, *Bixa orellana*, *Ipomoea batatas* *Vaccinium myrtillus*, *Buddleia officinalis*, *Cistancha salsa* or *Glycyrrhiza glabra* extract. Component b can be a green tea extract, myrecetin, querecetin or tannin. Component c can be an isoflavon or a water soluble carotenoid.

WO 01/85183 A2

Preparation for the prevention and treatment of ocular disorders

The present invention relates to a preparation for the prevention and/or treatment of ocular disorders, in particular cataracts, age-related macula degeneration (AMD) and glaucoma.

Cataracts are opacities of the lens and the onset of the disorder in patients is usually above 50 years of age. The opacities in the lens are aggregates of damaged and hence dysfunctional lens proteins, predominantly crystallines. Two mechanisms are responsible for the damage inflicted on the crystallines: oxidative stress, leading to destruction of the proteins, and high glucose or sorbitol levels of the lens, causing glycosilation of the crystallines, making them dysfunctional.

Excessive exposure of the lens to sunlight, nutrition status and smoking are the main risk factors for oxidative stress of the lens. High glucose and sorbitol levels have been established with diabetes patients. Current methods for the treatment of cataracts include lens extraction, costing about \$3.5 billion annually in the USA. Existing nutritional supplement formulae for the prevention of cataracts are usually based on antioxidants (vitamin E, vitamin C, β -carotene) and minerals that support antioxidant proteins (Zn, Se).

Age related macula degeneration (AMD) is a degenerative disorder of the macula lutea or yellow spot, which is the central part of the retina, with the highest visual acuity and concentration of cones. Two forms of AMD can be discriminated. Dry AMD or atrophic AMD is characterized by hard or soft drusen (deposits of cellular debris), changes in the retinal pigment epithelium or atrophy of the photoreceptors and the retinal pigment epithelium. Wet AMD is a more advanced form of AMD and is characterized by neovascularization and exudation of fluid. Two pigments are present in the macula and are responsible for its characteristic yellow color: lutein and zeaxanthin. These water soluble carotenoids are thought to protect the macula by absorbing high energy blue light and by their antioxidant properties. The macula is avascular and depends therefor on the choroid, which is the layer in the eye behind the retina, for its nutrient supply. Current supplement prevention formulae include mostly antioxidants and lutein.

Glaucoma is a collection of disorders which is caused by an increased intra ocular pressure (IOP). This pressure causes ischemic insults to the retina and irreversible damage to the ocular nerve. Common supplements for the prevention of glaucoma are based on antioxidants.

In view of the wide spread occurrence of the above mentioned disorders, there is a need for a preparation that can prevent or treat these disorders simultaneously. The present inventors have now found such a preparation that is particularly active against the above three disorders, cataracts, age related macula degeneration and glaucoma.

The present invention provides a preparation for the prevention and/or treatment of ocular disorders which comprises

- a. an aldose reductase inhibitor;
- b. an intra ocular pressure lowering component; and
- c. a component that increases ocular blood flow.

Component a; the aldose reductase inhibitor limits the reduction of glucose to sorbitol. Preferably this component is a *Chrysanthemum morifolium*, *Bixa orellana*, *Ipomoea batatas*, *Vaccinium myrtillus*, *Buddleia officinalis*, *Cistancha salsa* or *Glycyrrhizza glabra* extract.

Extracts from *Chrysanthemum morifolium* are flower extracts and should certainly comprise acacetin, diosmetin, luteoline or their glucosides and/or ellagic acid. The extract is prepared such that it contains 0.25 wt.% chlorogenic acid. Extracts from *Bixa orellana* should certainly comprise gallic acid and/or pyrogallol. Extracts from *Ipomoea batatas* should certainly comprise scopoletin and/or caffeic acid. Extracts of *Vaccinium myrtillus* are berry extracts and contain preferably at least 25 wt.% anthocyanosides (based on dry matter). The extract of *Buddleia officinalis* is preferably an alcohol/water extract of the flower bud. Such extracts can be obtained from the firm KING HERB. The extract of *Cistancha salsa* is preferably an alcohol/water extract of the stem, also available from KING HERB. The extract of *Glycyrrhizza glabra* is preferably an extract containing at least 12.7 wt.% glycyrrhizic acid. It can be obtained from ZANDU.

Suitability of the plant (extracts) as aldose reductase inhibitors for the object of the invention can also be determined by means of the assay as described in the examples hereafter. The extract should have an LC_{50} of 0.03 mg/ml at the most.

5 Consequently, according to the invention, the aldose reductase inhibitor comprises preferably at least a component selected from the group consisting of acacetin, diosmetin, luteoline, ellagic acid, gallic acid, pyrogallol, isoscutellarein, scopoletin, 3,5-dicaffeoylquinic acid and caffeic acid or their functional analogues, said functional analogues being glucosides, esters or salts thereof.

10

Preferably one or more of these components, in synthetic form but most preferably as extract, are preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.

15 Component b, the intra ocular pressure lowering component is a component selected from the group catechins, flavonoids and/or tannins. Preferably catechins, and most preferably in the form of a green tea extract is used, i.e. an extract rich in epigallocatechin or epigallocatechin gallate. Component b is alternatively myrecetin, quercetin or tannin. Component b is preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.

20 Component c, the component that increases ocular blood flow is an isoflavon or a water soluble carotenoid. The isoflavon is preferably puerarin or an equivalent thereof. This isoflavon can be extracted from the roots of *Pueraria lobata*, also known as kudzu. This extract is traditionally used to assist in alcohol withdrawal support and to prevent or treat angina and high blood pressure. The water soluble carotenoid is preferably crocetin or crocin or an
25 equivalent thereof. Component c is preferably administered in a daily dose of 0.01 to 50 mg/day, preferably 0.1 to 10 mg/day.

The preparation of the invention can further contain, beside the above mentioned components a, b and c, lutein, zeaxanthine and/or one or more antioxidant. Lutein and zeaxanthine can be
30 present in an amount of 0.01 to 50 mg/day, preferably 0.1 to 20 mg/day. Preferably lutein is included, in particular as a stable and readily absorbable form, such as a lutein ester.

Antioxidants can be vitamin C, vitamin E, zinc, β -carotene, copper, and selenium. An extract with antioxidant activity is for instance bilberry extract.

The preparation can also contain one or more of vitamin A, riboflavin, ginkgo biloba, N-acetylcysteine, vitamin B6, vitamin B12 and folic acid.

The preparation of the invention can be used in the treatment and/or prevention of ocular disorders, in particular in the treatment or prevention of cataracts, age related macula degeneration and glaucoma.

The preparation of the invention is a pharmaceutical or dietary preparation, in particular a nutritional supplement. The nutritional supplement that is administered on a daily basis to prevent the ocular disorders. Such a supplement can have the form of a tablet, drink, powder, bar, cookie, cereal, etc., as is known to the skilled person. Also foods which contain the above ingredients are possible.

Examples

Assay aldose reductase inhibition

The inhibitory effects of herbal extracts towards aldose reductase are assessed with the following in vitro assay.

DL-glyceraldehyde, which is used as a model system for glucose (Dufrane, et al 1984), aldose reductase, obtained from rat lenses (Inuma et al 1989) and NADPH are incubated at 37 °C.

The absorption of NADPH at 340 nm is spectrophotometrically followed for 15 minutes. This decay is proportional to the enzyme activity of aldose reductase, since NADPH and glyceraldehyde react stoichiometrically.

The % inhibition of different sample concentrations can then be calculated with differences in the slopes between sample and blank (without sample). By linearization of the dose response curve (% inhibition in probit against log concentration) the LC_{50} value can be calculated. The LC_{50} value is defined as that concentration of the sample that inhibits aldose reductase with

50%. The data for the herbal extracts was compared to quercitrin, a standard commonly used in aldose reductase inhibition assays. The LC_{50} values for the samples are listed in Table 1.

Table 1

Sample	LC_{50} (mg/ml)
quercitrin	0.0004 ± 0.0001
<i>Chrysanthemum morifolium</i>	0.0036 ± 0.0015
<i>Vaccinium myrtillus</i>	0.0045 ± 0.0022
<i>Buddleia officinalis</i>	0.0027 ± 0.0007
<i>Cistancha salsa</i>	0.0160 ± 0.0005
<i>Glycyrrhizza glabra</i>	0.0081 ± 0.0028

5 Formulation example

An example composition of the preparation is:

Pueraria Root extract 5 %	50 mg
Green Tea extract 80 % polyphenols	20 mg
Chrysanthemum morifolium extract 4:1	20 mg
Vitamin A	2500 IU
Beta-carotene	2500 IU
Lutein	10 mg
Riboflavin	5 mg
Vitamin C	600 mg
Vitamin E	220 IU
Zinc	15 mg
Copper	3 mg
Selenium	70 μ g
Bilberry extract	200 mg
Gingko biloba	30 mg
N-acetylcysteine	200 mg
Vitamin B6	4 mg
Vitamin B12	4 μ g
Folic acid	600 μ g

Claims

1. Preparation for the prevention and/or treatment of ocular disorders which comprises
 - a. an aldose reductase inhibitor;
 - b. an intra ocular pressure lowering component; and
 - c. a component that increases ocular blood flow.
2. Preparation according to claim 1, wherein the aldose reductase inhibitor is a *Chrysanthemum morifolium*, *Bixa orellana* *Ipomoea batatas*, *Vaccinium myrtillus*, *Buddleia officinalis*, *Cistancha salsa* or *Glycyrhizza glabra* extract.
3. Preparation according to claim 2, wherein the extract from *Chrysanthemum morifolium* comprises acacetin, diosmetin, luteoline or their glucosides and/or ellagic acid.
4. Preparation according to claim 2, wherein the extract from *Bixa orellana* comprises gallic acid and/or pyrogallol.
5. Preparation according to claim 2, wherein the extract from *Ipomoea batatas* comprises scopoletin and/or caffeic acid.
6. Preparation according to claim 1, wherein the aldose reductase inhibitor comprises at least a component selected from the group consisting of acacetin, diosmetin, luteoline, ellagic acid, gallic acid, pyrogallol, isoscutellarein, scopoletin, 3,5-dicaffeoylquinic acid and caffeic acid or their functional analogues, said functional analogues being glucosides, esters or salts thereof.
7. Preparation according to any of the preceding claims, wherein the aldose reductase inhibitor is a *Chrysanthemum morifolium* extract.
8. Preparation according to any of claims 1 to 7, wherein the intra ocular pressure lowering component is a green tea extract.

9. Preparation according to claim 8, wherein the intra ocular pressure lowering component is a catechin, in particular epigallocatechin or epigallocatechin gallate.

5 10. Preparation according to any of claims 1 to 7, wherein the intra ocular pressure lowering component is myrecetin, quercetin or tannin.

11. Preparation according to any of claims 1 to 10, wherein the component that increases ocular blood flow is an isoflavon or a water soluble carotenoid.

10

12. Preparation according to claim 11, wherein the isoflavon is puerarin.

13. Preparation according to claim 11, wherein the water soluble carotenoid is crocetin or crocin.

15

14. Preparation according to any of the preceding claims, comprising

- a. Chrysanthemum morifolium extract;
- b. green tea extract; and
- c. puerarin.

20

15. Preparation according to any of claims 1 to 14, further comprising lutein.

16. Preparation according to any of claims 1 to 15, further comprising one or more antioxidants.

25

17. Use of a preparation according to any of claims 1 to 16 for the treatment and/or prevention of ocular disorders.

18. Use of a preparation according to any of claims 1 to 16 for the treatment and/or
30 prevention of cataracts.

19. Use of a preparation according to any of claims 1 to 16 for the treatment and/or prevention of age related macula degeneration.

20. Preparation according to any of claims 1 to 16 for the treatment and/or prevention of
5 glaucoma.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/085183 A3

(51) International Patent Classification⁷: **A61P 27/02**,
27/04, 27/06, 27/12, A61K 35/78

(21) International Application Number: PCT/NL01/00348

(22) International Filing Date: 8 May 2001 (08.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/566,385 8 May 2000 (08.05.2000) US

(71) Applicant (for all designated States except US): N.V. NU-
TRICIA [NL/NL], P.O. Box 1, NL-2700 MA Zoetermeer
(NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VERDEGEM, Peter,
Julien, Edward [NL/NL]; Zwanenveld 2413, NL-6538 PA
Nijmegen (NL).

(74) Agent: JORRITSMA, Ruurd; Nederlandsch Octroibu-
reau, Scheveningsweg 82, P.O. Box 29720, NL-2502 LS
The Hague (NL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
15 August 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION FOR THE PREVENTION AND TREATMENT OF OCULAR DISORDERS

(57) Abstract: The present invention relates to a preparation for the prevention and/or treatment of ocular disorders which comprises:
a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood
flow. Component a can be *Chrysanthemum morifolium*, *Bixa orellana*, *Ipomoea batatas* *Vaccinium myrtillus*, *Buddleia officinalis*,
Cistancha salsa or *Glycyrrhiza glabra* extract. Component b can be a green tea extract, myrecetin, querecetin or tannin. Component
c can be an isoflavon or a water soluble carotenoid.

WO 01/085183 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/NL 01/00348

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P27/02 A61P27/04 A61P27/06 A61P27/12 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

PAJ, EPO-Internal, WPI Data, BIOSIS, FSTA, CHEM ABS Data, EMBASE, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 78783 A (HAUSER INC ;UNIV TEXAS (US)) 25 October 2001 (2001-10-25) claims	1-3, 5-11,16, 20
P,X	EP 1 072 265 A (MEDIS S R L MEDICAL INFUSION S) 31 January 2001 (2001-01-31) claims	1-3,7-9, 11,16,20
P,X	WO 00 59523 A (HELLER LYRA ;METAGENICS INC (US); KRUMHAR KIM CARLETON (US)) 12 October 2000 (2000-10-12) claims 1,4	1-3, 6-11,16, 20
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

10 May 2002

Date of mailing of the international search report

03/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Skjöldebrand, C

INTERNATIONAL SEARCH REPORT

International Application No.

I/NL 01/00348

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 968 709 A (LANATECH) 5 January 2000 (2000-01-05) abstract claims 1,7-10	1,2,4-6, 8-11,16, 20
X	US 5 972 993 A (PTCHELINTSEV DMITRI) 26 October 1999 (1999-10-26) abstract; claims 1,6	1-3,5-8, 10,11, 15,16,20
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 01, 31 January 2000 (2000-01-31) & JP 11 292785 A (NOEVIR CO LTD), 26 October 1999 (1999-10-26) abstract	1,2,4,6, 8,10,11, 16,20
X	EP 0 906 761 A (ARCHER DANIELS MIDLAND CO) 7 April 1999 (1999-04-07) claims 1,8,9	1,2,4-9, 11,16,20
X	SRIVASTAVA ANIL ET AL: "Chemistry, pharmacology and uses of Bixa orellana: A review." JOURNAL OF MEDICINAL AND AROMATIC PLANT SCIENCES, vol. 21, no. 4, December 1999 (1999-12), pages 1145-1154, XP001070002 the whole document	1-16,20
Y,P	CN 1 291 495 A (TANG XIUJUN) 18 April 2001 (2001-04-18) abstract	1-16,20
Y	DE 199 50 327 A (WERKLUST & BEHEER WASSENAAR B) 20 April 2000 (2000-04-20) abstract; claims	1-16,20
Y	WO 99 38497 A (KATO ICHIE ;UENO SEIYAKU OYO KENKYUJO KK (JP); UENO RYUJI (US)) 5 August 1999 (1999-08-05) the whole document	1-16,20
P,X	JOUSSEN ANTONIA M ET AL: "Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids." EXPERIMENTAL EYE RESEARCH, vol. 71, no. 5, November 2000 (2000-11), pages 483-487, XP001070101 ISSN: 0014-4835 page 483, paragraphs ABSTRACT,INTRODUCTION	1-16,20

-/--

INTERNATIONAL SEARCH REPORT

International Application No

P L 01/00348

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HODGES L C ET AL: "INTRAOCULAR PRESSURE-LOWERING ACTIVITY OF PHENOLIC ANTIOXIDANTS IN NORMOTENSIVE RABBITS" CURRENT EYE RESEARCH, IRL PRESS, OXFORD, GB, vol. 19, no. 3, September 1999 (1999-09), pages 234-240, XP000978437 ISSN: 0271-3683 the whole document</p>	1-16,20

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1

Present claim 1 relates to a compounds defined by reference to a desirable characteristic or property, namely "aldose reductase inhibitor", an "intraocular pressure lowering component" and a "component that increases ocular blood flow".

Because of the functional definition of claim 1, a full search search over the whole of the claimed scope is impossible, due to the problem of knowing what compounds fall under these definitions. Consequently, the search has been carried out for those parts of the claims relating to the compounds/extracts defined in claims 2-14, as well as keywords relating to the above functional definitions.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IL 01/00348

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0178783	A	25-10-2001	AU 5160201 A WO 0178783 A2	30-10-2001 25-10-2001
EP 1072265	A	31-01-2001	EP 1072265 A1 EP 1074254 A2	31-01-2001 07-02-2001
WO 0059523	A	12-10-2000	AU 4224600 A BR 0006024 A EP 1093376 A1 WO 0059523 A1	23-10-2000 06-11-2001 25-04-2001 12-10-2000
EP 0968709	A	05-01-2000	FR 2780647 A1 DE 968709 T1 EP 0968709 A1 ES 2140368 T1 US 6231877 B1	07-01-2000 08-06-2000 05-01-2000 01-03-2000 15-05-2001
US 5972993	A	26-10-1999	NONE	
JP 11292785	A	26-10-1999	NONE	
EP 0906761	A	07-04-1999	US 6261565 B1 AU 8787998 A BR 9805069 A CA 2249501 A1 EP 0906761 A2 JP 11221048 A NO 984591 A ZA 9808962 A	17-07-2001 22-04-1999 21-03-2000 02-04-1999 07-04-1999 17-08-1999 06-04-1999 13-09-1999
CN 1291495	A	18-04-2001	NONE	
DE 19950327	A	20-04-2000	NL 1010351 C2 DE 19950327 A1 NL 1010351 A1	08-01-2001 20-04-2000 28-04-2000
WO 9938497	A	05-08-1999	AU 2184499 A BR 9907715 A CA 2318516 A1 CN 1295476 T EP 1161942 A2 EP 1004307 A2 JP 11279062 A WO 9938497 A2 NO 20003786 A TR 200002209 T2 ZA 9900733 A	16-08-1999 17-10-2000 05-08-1999 16-05-2001 12-12-2001 31-05-2000 12-10-1999 05-08-1999 24-07-2000 21-11-2000 02-08-1999